Tetradecylthioacetic acid prevents the inflammatory response in two-kidney, one-clip hypertension

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 294, Issue 2, 2008, Pages

  Bivol, Liliana M ^a,b   Berge, Rolf K ^a,b   Iversen, Bjarne M ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cytokines; Nitric oxide; Nuclear factor B; Reactive oxygen species

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TETRADECYLTHIOACETIC ACID; THIOACETIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; DRUG MECHANISM; FOOD INTAKE; HYPERTENSION; KIDNEY CORTEX; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BODY WEIGHT; CHEMOKINE CCL2; DINOPROST; DISEASE MODELS, ANIMAL; EATING; FREE RADICAL SCAVENGERS; HYPERTENSION, RENAL; INTERLEUKIN-1BETA; INTERLEUKIN-6; KIDNEY CORTEX; MALE; NEPHRITIS; NF-KAPPA B P50 SUBUNIT; NITRATES; NITRIC OXIDE; NITRITES; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; SODIUM, DIETARY; SULFIDES; SURGICAL INSTRUMENTS; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38949170979     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00590.2007     Document Type: Article

References (46)

1. Aarsland A, Aarsaether N, Bremer J, Berge RK. Alkylthioacetic acids (3-thia fatty acids) as nonbeta-oxidizable fatty acid analogues: a new group of hypolipidemic drugs. III. Dissociation of cholesterol- and triglyceride-lowering effects and the induction of peroxisomal beta-oxidation. J Lipid Res 30: 1711-1718, 1989.
2. Agarwal R, Campbell RC, Warnock DG. Oxidative stress in hypertension and chronic kidney disease: role of angiotensin II. Semin Nephrol 24: 101-114, 2004.
3. Arendshorst WJ, Brannstrom K, Ruan X. Actions of angiotensin II on the renal microvasculature. J Am Soc Nephrol, 10 Suppl 11: S149-S161, 1999.
4. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12: 141-179, 1994.
5. Berge K, Tronstad KJ, Flindt EN, Rasmussen TH, Madsen L, Kristiansen K, Berge RK. Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways. Carcinogenesis 22: 1747-1755, 2001.
6. Berge RK, Hvattum E. Impact of cytochrome P450 system on lipoprotein metabolism. Effect of abnormal fatty acids (3-thia fatty acids). Pharmacol Ther 61: 345-383, 1994.
7. Berge RK, Skorve J, Tronstad KJ, Berge K, Gudbrandsen OA, Grav H. Metabolic effects of thia fatty acids. Curr Opin Lipidol 13: 295-304, 2002.
8. Bivol LM, Berge RK, Iversen BM. Differential effect of tetradecythioacetic acid on the renin-angiotensin system and blood pressure in SHR and 2-kidney, 1-clip hypertension. Am J Physiol Renal Physiol 293: F839-F845, 2007.
9. Bivol LM, Vagnes OB, Iversen BM. The renal vascular response to ANG II injection is reduced in the nonclipped kidney of two-kidney, one-clip hypertension. Am J Physiol Renal Physiol 289: F393-F400, 2005.
10. Blais V, Rivest S. Inhibitory action of nitric oxide on circulating tumor necrosis factor-induced NF-kappaB activity and COX-2 transcription in the endothelium of the brain capillaries. J Neuropathol Exp Neurol 60: 893-905, 2001.
11. Brannstrom K, Morsing P, Arendshorst WJ. Candesartan normalizes exaggerated tubuloglomerular feedback activity in young spontaneously hypertensive rats. J Am Soc Nephrol 10, Suppl 11: S213-S219, 1999.
12. Chabrashvili T, Kitiyakara C, Blau J, Karber A, Aslam S, Welch WJ, Wilcox CS. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol 285: R117-R124, 2003.
13. Chandar J, Abitbol C, Montane B, Zilleruelo G. Angiotensin blockade as sole treatment for proteinuric kidney disease in children. Nephrol Dial Transplant 22: 1332-1337, 2007.
14. Costanzo A, Moretti F, Burgio VL, Bravi C, Guido F, Levrero M, Puri PL. Endothelial activation by angiotensin II through NFkappaB and p38 pathways: Involvement of NFkappaB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. J Cell Physiol 195: 402-410, 2003.
15. Delanty N, Reilly MP, Pratico D, Lawson JA, McCarthy JF, Wood AE, Ohnishi ST, Fitzgerald DJ, FitzGerald GA. 8-epi PGF2 alpha generation during coronary reperfusion. A potential quantitative marker of oxidant stress in vivo. Circulation 95: 2492-2499, 1997.
16. Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, Schiffrin EL. PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 40: 866-871, 2002.
17. Dyroy E, Yndestad A, Ueland T, Halvorsen B, Damas JK, Aukrust P, Berge RK. Antiinflammatory effects of tetradecylthioacetic acid involve both peroxisome proliferator-activated receptor alpha-dependent and -independent pathways. Arterioscler Thromb Vasc Biol 25: 1364-1369, 2005.
18. Fredriksen J, Ueland T, Dyroy E, Halvorsen B, Melby K, Melbye L, Skalhegg BS, Bohov P, Skorve J, Berge RK, Aukrust P, Froland SS. Lipid-lowering and anti-inflammatory effects of tetradecylthioacetic acid in HIV-infected patients on highly active antiretroviral therapy. Eur J Clin Invest 34: 709-715, 2004.
19. Gudbrandsen OA, Hultstrom M, Leh S, Monica Bivol L, Vagnes O, Berge RK, Iversen BM. Prevention of hypertension and organ damage in 2-kidney, 1-clip rats by tetradecylthioacetic acid. Hypertension 48: 460-466, 2006.
20. Iversen BM, Heyeraas KJ, Sekse I, Andersen KJ, Ofstad J. Autoregulation of renal blood flow in two-kidney, one-clip hypertensive rats. Am J Physiol Renal Fluid Electrolyte Physiol 251: F245-F250, 1986.
21. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 59: 251-287, 2007.
22. Leh S, Vaagnes O, Margolin SB, Iversen BM, Forslund T. Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats. Nephrol Dial Transplant 20: 71-82, 2005.
23. Madsen L, Guerre-Millo M, Flindt EN, Berge K, Tronstad KJ, Bergene E, Sebokova E, Rustan AC, Jensen J, Mandrup S, Kristiansen K, Klimes I, Staels B, Berge RK. Tetradecylthioacetic acid prevents high fat diet induced adiposity and insulin resistance. J Lipid Res 43: 742-750, 2002.
24. Manhiani MM, Quigley JE, Socha MJ, Motamed K, Imig JD. IL6 suppression provides renal protection independent of blood pressure in a murine model of salt-sensitive hypertension. Kidney Blood Press Res 30: 195-202, 2007.
25. Martinez-Maldonado M. Pathophysiology of renovascular hypertension. Hypertension 17: 707-719, 1991.
26. Marzinzig M, Nussler AK, Stadler J, Marzinzig E, Barthlen W, Nussler NC, Beger HG, Morris SM Jr, Bruckner UB. Improved methods to measure end products of nitric oxide in biological fluids: nitrite, nitrate, and S-nitrosothiols. Nitric Oxide 1: 177-189, 1997.
27. Minuz P, Patrignani P, Gaino S, Degan M, Menapace L, Tommasoli R, Seta F, Capone ML, Tacconelli S, Palatresi S, Bencini C, Del Vecchio C, Mansueto G, Arosio E, Santonastaso CL, Lechi A, Morganti A, Patrono C. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 106: 2800-2805, 2002.
28. Mishra A, Chaudhary A, Sethi S. Oxidized omega-3 fatty acids inhibit NF-kappaB activation via a PPARalpha-dependent pathway. Arterioscler Thromb Vasc Biol 24: 1621-1627, 2004.
29. Mitchell KD, Botros FT, Navar LG. Intrarenal renin-angiotensin system and counteracting protective mechanisms in angiotensin II-dependent hypertension. Acta Physiol Hung 94: 31-48, 2007.
30. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ 2nd. A series of prostaglandin F2-like compounds are produced in vivo in humans by a noncyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 87: 9383-9387, 1990.
31. Navar LG. The role of the kidneys in hypertension. J Clin Hypertens (Greenwich) 7: 542-549, 2005.
32. Navar LG, Harrison-Bernard LM, Nishiyama A, Kobori H. Regulation of intrarenal angiotensin II in hypertension. Hypertension 39: 316-322, 2002.
33. Navar LG, Von Thun AM, Zou L, el-Dahr SS, Mitchell KD. Enhancement of intrarenal angiotensin II levels in 2 kidney 1 clip and angiotensin II induced hypertension. Blood Press Suppl 2: 88-92, 1995.
34. Noiri E, Peresleni T, Miller F, Goligorsky MS. In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat kidney against ischemia. J Clin Invest 97: 2377-2383, 1996.
35. Patzak A, Kleinmann F, Lai EY, Kupsch E, Skelweit A, Mrowka R. Nitric oxide counteracts angiotensin II induced contraction in efferent arterioles in mice. Acta Physiol Scand 181: 439-444, 2004.
36. Pauletto P, Rattazzi M. Inflammation and hypertension: the search for a link. Nephrol Dial Transplant 21: 850-853, 2006.
37. Perez De Lema G, De Wit C, Cohen CD, Nieto E, Molina A, Banas B, Luckow B, Vicente AB, Mampaso F, Schlondorff D. Angiotensin inhibition reduces glomerular damage and renal chemokine expression in MRL/lpr mice. J Pharmacol Exp Ther 307: 275-281, 2003.
38. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 10: 321-329, 2001.
39. Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, Egido J. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl 82: 12-22, 2002.
40. Savoia C, Schiffrin EL. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci (Lond) 112: 375-384, 2007.
41. Skurk T, van Harmelen V, Hauner H. Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-kappaB. Arterioscler Thromb Vasc Biol 24: 1199-1203, 2004.
42. Tham DM, Martin-McNulty B, Wang YX, Wilson DW, Vergona R, Sullivan ME, Dole W, Rutledge JC. Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics 11: 21-30, 2002.
43. Todorov VT, Volkl S, Muller M, Bohla A, Klar J, Kunz-Schughart LA, Hehlgans T, Kurtz A. Tumor necrosis factor-alpha activates NFkappaB to inhibit renin transcription by targeting cAMP-responsive element. J Biol Chem 279: 1458 -1467, 2004.
44. Welch WJ, Mendonca M, Aslam S, Wilcox CS. Roles of oxidative stress and AT1 receptors in renal hemodynamics and oxygenation in the post-clipped 2K,1C kidney. Hypertension 41: 692-696, 2003.
45. Welch WJ, Wilcox CS. AT1 receptor antagonist combats oxidative stress and restores nitric oxide signaling in the SHR. Kidney Int 59: 1257-1263, 2001.
46. Zou LX, Imig JD, Hymel A, Navar LG. Renal uptake of circulating angiotensin II in Val5-angiotensin II infused rats is mediated by AT1 receptor. Am J Hypertens 11: 570-578, 1998.